BNGO
Bionano Genomics, Inc. [BNGO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BNGO Stock Summary
Top 10 Correlated ETFs
BNGO
Top 10 Correlated Stocks
BNGO
In the News
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bionano Genomics, Inc. (BNGO) Presents at Stifel Healthcare Conference (Transcript)
Bionano Genomics, Inc. (NASDAQ:BNGO ) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two.
3 Stocks That Are Poised to Generate Outsized Returns
In general, stocks generate outsized returns because the Street has been overly bearish on their outlook. Due to the Street's overdone high interest rate concerns, it's now unduly pessimistic about many growth equities with great futures.
Bionano Genomics, Inc. (BNGO) Q3 2023 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded.
Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.
3 Deeply Undervalued Growth Stocks
One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks at this point.
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know
Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The 3 Best High-Risk, High-Reward Stocks to Buy Now: September 2023
Due to a combination of worries about high-interest rates, China's decision to prevent some government employees from using Apple's (NASDAQ: AAPL ) iPhones at work, and the fact that September is historically a very bad month for equities. many high-risk, high-reward stocks have taken a beating recently.
7 F-Rated Meme Stocks to Avoid Like the Plague
Sometimes I really question why we're still talking about meme stocks. When will investors learn that the unpredictable nature of meme stocks nearly always makes them a bad investment choice?
These Are the ONLY 3 Meme Stocks to Consider in August 2023
Meme stocks feel like a relic of a bygone era. Indeed, all of the meme stocks that I can think of have been totally crushed since their heyday.
BNGO Financial details
BNGO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 16.96 | 6.76 | 0.82 | 0.65 | 0.96 | |
| Net income per share | -26.14 | -19.92 | -3.95 | -2.62 | -4.58 | |
| Operating cash flow per share | -28.18 | -19.72 | -3.68 | -2.6 | -4.32 | |
| Free cash flow per share | -28.65 | -19.76 | -3.68 | -2.65 | -4.43 | |
| Cash per share | 23.35 | 11.56 | 3.69 | 9.05 | 3.91 | |
| Book value per share | 14.32 | 2.41 | 3.37 | 12.18 | 8.62 | |
| Tangible book value per share | 14.32 | 2.38 | 2.54 | 9.18 | 4.53 | |
| Share holders equity per share | 14.32 | 2.41 | 3.37 | 12.18 | 8.62 | |
| Interest debt per share | 14.71 | 14.89 | 1.81 | 0.42 | 0.41 | |
| Market cap | 37.08M | 18.57M | 321.09M | 827.58M | 422.25M | |
| Enterprise value | 29.59M | 21.28M | 298.97M | 813.7M | 428.82M | |
| P/E ratio | -2 | -0.62 | -7.81 | -11.43 | -3.18 | |
| Price to sales ratio | 3.09 | 1.83 | 37.76 | 46.03 | 15.19 | |
| POCF ratio | -1.86 | -0.63 | -8.38 | -11.51 | -3.38 | |
| PFCF ratio | -1.83 | -0.63 | -8.38 | -11.28 | -3.3 | |
| P/B Ratio | 3.66 | 5.14 | 9.15 | 2.45 | 1.69 | |
| PTB ratio | 3.66 | 5.14 | 9.15 | 2.45 | 1.69 | |
| EV to sales | 2.47 | 2.1 | 35.16 | 45.25 | 15.42 | |
| Enterprise value over EBITDA | -1.4 | -0.82 | -7.76 | -10.58 | -3.29 | |
| EV to operating cash flow | -1.48 | -0.72 | -7.8 | -11.31 | -3.44 | |
| EV to free cash flow | -1.46 | -0.72 | -7.8 | -11.09 | -3.35 | |
| Earnings yield | -0.5 | -1.61 | -0.13 | -0.09 | -0.31 | |
| Free cash flow yield | -0.55 | -1.59 | -0.12 | -0.09 | -0.3 | |
| Debt to equity | 0.89 | 5.54 | 0.47 | 0.03 | 0.05 | |
| Debt to assets | 0.36 | 0.66 | 0.27 | 0.03 | 0.04 | |
| Net debt to EBITDA | 0.36 | -0.1 | 0.57 | 0.18 | -0.05 | |
| Current ratio | 5.09 | 1.07 | 5.23 | 12.47 | 4.38 | |
| Interest coverage | -14.78 | -11.32 | -15.3 | -83.17 | -441.94 | |
| Income quality | 1.08 | 0.99 | 0.93 | 0.99 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.18 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.79 | 0.9 | 1.21 | 1.25 | 1.76 | |
| Intangibles to total assets | 0 | 0 | 0.14 | 0.22 | 0.39 | |
| Capex to operating cash flow | 0.02 | 0 | 0 | 0.02 | 0.03 | |
| Capex to revenue | -0.03 | -0.01 | 0 | -0.08 | -0.12 | |
| Capex to depreciation | -0.25 | -0.05 | 0 | -0.43 | -0.34 | |
| Stock based compensation to revenue | 0.11 | 0.13 | 0.18 | 0.54 | 0.81 | |
| Graham number | 91.78 | 32.88 | 17.28 | 26.78 | 29.83 | |
| ROIC | -1.07 | -1.1 | -0.75 | -0.2 | -0.49 | |
| Return on tangible assets | -0.75 | -0.99 | -0.79 | -0.25 | -0.7 | |
| Graham Net | 8.16 | -1.91 | 1.61 | 7.97 | 2.6 | |
| Working capital | 18.5M | 1.95M | 37.85M | 250.57M | 121.41M | |
| Tangible asset value | 10.14M | 3.57M | 26.43M | 254.12M | 130.97M | |
| Net current asset value | 8.36M | 1.62M | 21.42M | 232.43M | 99.19M | |
| Invested capital | 0.89 | 5.54 | 0.47 | 0.03 | 0.05 | |
| Average receivables | 3.93M | 5.42M | 4.55M | 3.85M | 5.98M | |
| Average payables | 1.83M | 2.03M | 2.81M | 6.31M | 11.12M | |
| Average inventory | 1.38M | 2.26M | 3.38M | 7.85M | 21.07M | |
| Days sales outstanding | 137.3 | 228.23 | 119.12 | 100.16 | 92.19 | |
| Days payables outstanding | 56.64 | 145.56 | 186.61 | 250.87 | 209.31 | |
| Days of inventory on hand | 44.77 | 185.71 | 211.2 | 320.5 | 496.99 | |
| Receivables turnover | 2.66 | 1.6 | 3.06 | 3.64 | 3.96 | |
| Payables turnover | 6.44 | 2.51 | 1.96 | 1.45 | 1.74 | |
| Inventory turnover | 8.15 | 1.97 | 1.73 | 1.14 | 0.73 | |
| ROE | -1.82 | -8.26 | -1.17 | -0.21 | -0.53 | |
| Capex per share | -0.47 | -0.04 | 0 | -0.05 | -0.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.25 | 0.28 | 0.25 | 0.28 | 0.27 | |
| Net income per share | -1.1 | -1.3 | -1.23 | -1.24 | -3.22 | |
| Operating cash flow per share | -1.02 | -1.16 | -1.07 | -1.17 | -0.75 | |
| Free cash flow per share | -1.03 | -1.21 | -1.09 | -1.18 | -0.75 | |
| Cash per share | 6.23 | 3.81 | 3.17 | 2.45 | 1.82 | |
| Book value per share | 9.74 | 8.4 | 7.66 | 6.82 | 3.4 | |
| Tangible book value per share | 7.01 | 4.41 | 3.8 | 3.17 | 2.38 | |
| Share holders equity per share | 9.74 | 8.4 | 7.66 | 6.82 | 3.4 | |
| Interest debt per share | 0.36 | 0.4 | 0.37 | 0.34 | 0.29 | |
| Market cap | 529.19M | 433.55M | 335.27M | 192.14M | 106.05M | |
| Enterprise value | 511.41M | 440.13M | 342.34M | 187.94M | 81.63M | |
| P/E ratio | -4.16 | -2.8 | -2.26 | -1.23 | -0.24 | |
| Price to sales ratio | 73.28 | 52.78 | 45.22 | 22.18 | 11.38 | |
| POCF ratio | -17.95 | -12.56 | -10.34 | -5.24 | -4.03 | |
| PFCF ratio | -17.78 | -12.02 | -10.23 | -5.16 | -4.02 | |
| P/B Ratio | 1.88 | 1.74 | 1.45 | 0.89 | 0.89 | |
| PTB ratio | 1.88 | 1.74 | 1.45 | 0.89 | 0.89 | |
| EV to sales | 70.82 | 53.58 | 46.17 | 21.7 | 8.76 | |
| Enterprise value over EBITDA | -17.47 | -11.96 | -9.25 | -5.3 | -2.59 | |
| EV to operating cash flow | -17.35 | -12.75 | -10.56 | -5.12 | -3.1 | |
| EV to free cash flow | -17.18 | -12.2 | -10.45 | -5.05 | -3.1 | |
| Earnings yield | -0.06 | -0.09 | -0.11 | -0.2 | -1.06 | |
| Free cash flow yield | -0.06 | -0.08 | -0.1 | -0.19 | -0.25 | |
| Debt to equity | 0.04 | 0.05 | 0.05 | 0.05 | 0.09 | |
| Debt to assets | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | |
| Net debt to EBITDA | 0.61 | -0.18 | -0.19 | 0.12 | 0.78 | |
| Current ratio | 6.51 | 4.38 | 3.74 | 3.66 | 2.6 | |
| Interest coverage | -440.4 | -500.36 | -497.93 | -530.24 | -1.59K | |
| Income quality | 0.93 | 0.89 | 0.87 | 0.94 | 0.23 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.76 | 1.71 | 1.88 | 1.69 | 1.48 | |
| Intangibles to total assets | 0.24 | 0.39 | 0.4 | 0.42 | 0.2 | |
| Capex to operating cash flow | 0.01 | 0.05 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.04 | -0.19 | -0.05 | -0.06 | -0.01 | |
| Capex to depreciation | -0.12 | -0.55 | -0.11 | -0.15 | -0.02 | |
| Stock based compensation to revenue | 0.84 | 0.67 | 0.52 | 0.45 | 0.43 | |
| Graham number | 15.53 | 15.69 | 14.56 | 13.77 | 15.69 | |
| ROIC | -0.11 | -0.14 | -0.15 | -0.17 | -0.81 | |
| Return on tangible assets | -0.13 | -0.2 | -0.21 | -0.25 | -0.77 | |
| Graham Net | 5.36 | 2.53 | 1.88 | 1.35 | 0.58 | |
| Working capital | 184.7M | 121.41M | 104.42M | 89.08M | 64.34M | |
| Tangible asset value | 202.69M | 130.97M | 114.85M | 99.92M | 83.23M | |
| Net current asset value | 176.24M | 99.19M | 81.89M | 65.95M | 41.63M | |
| Invested capital | 0.04 | 0.05 | 0.05 | 0.05 | 0.09 | |
| Average receivables | 5.34M | 6.43M | 6.9M | 7.2M | 8.14M | |
| Average payables | 8.55M | 10.97M | 14.16M | 13.85M | 13.64M | |
| Average inventory | 22.82M | 27.4M | 31.44M | 32.78M | 29.44M | |
| Days sales outstanding | 72.65 | 76.93 | 82.29 | 79.1 | 83.73 | |
| Days payables outstanding | 156.44 | 175.98 | 265.71 | 168.73 | 210.57 | |
| Days of inventory on hand | 416.51 | 417.86 | 557.56 | 459.67 | 362.1 | |
| Receivables turnover | 1.24 | 1.17 | 1.09 | 1.14 | 1.07 | |
| Payables turnover | 0.58 | 0.51 | 0.34 | 0.53 | 0.43 | |
| Inventory turnover | 0.22 | 0.22 | 0.16 | 0.2 | 0.25 | |
| ROE | -0.11 | -0.16 | -0.16 | -0.18 | -0.95 | |
| Capex per share | -0.01 | -0.05 | -0.01 | -0.02 | 0 |
BNGO Frequently Asked Questions
What is Bionano Genomics, Inc. stock symbol ?
Bionano Genomics, Inc. is a US stock , located in San diego of Ca and trading under the symbol BNGO
Is Bionano Genomics, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $262.5. The lowest prediction is $175 and the highest is $350
What is BNGO stock prediction ?
What is Bionano Genomics, Inc. stock quote today ?
Bionano Genomics, Inc. stock price is $1.51 today.
Is Bionano Genomics, Inc. stock public?
Yes, Bionano Genomics, Inc. is a publicly traded company.
Company Profile
- Volume Average 896.24K
- Market Capitalization 64.09M
- Employee 388
- CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.
- Headquarters San Diego,CA,US
- IPO Date 2018-08-21
-
Website
https://www.bionanogenomics.com 
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
